Lorraine Kalia
Affiliations: | 2009-2010 | Neurology | MGH & Harvard Medical School, Boston, MA, United States |
Google:
"Lorraine Kalia"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mestre TA, Kalia LV. (2023) α-synuclein seed amplification in Parkinson's disease. The Lancet. Neurology. 22: 984-985 |
| Nim S, O'Hara DM, Corbi-Verge C, et al. (2023) Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. Nature Communications. 14: 2150 |
| Chen KS, Menezes K, Rodgers JB, et al. (2021) Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Molecular Neurodegeneration. 16: 77 |
| Barbuti PA, Barker RA, Brundin P, et al. (2021) Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society |
| O'Hara DM, Kapadia M, Ping S, et al. (2021) Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis. Journal of Visualized Experiments : Jove |
| Visanji NP, Madan P, Lacoste AMB, et al. (2020) Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiology and Drug Safety |
| Mylvaganam S, Earnshaw R, Heymann G, et al. (2020) C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. Current Neuropharmacology |
| Friesen EL, Zhang YT, Earnshaw R, et al. (2020) BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. Frontiers in Cell and Developmental Biology. 8: 716 |
| O'Hara DM, Pawar G, Kalia SK, et al. (2020) LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease? Frontiers in Neuroscience. 14: 577 |
| Maclagan LC, Visanji NP, Cheng Y, et al. (2020) Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety |